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Deviations from the expected relationship
between serum FGF23 and other markers
in children with CKD: a cross-sectional
study
Daisy Liu1, Ana Catalina Alvarez-Elías2,5,6, Brooke Wile2, Vladimir Belostotsky1 and Guido Filler2,3,4,7*
Abstract
Background: High levels of fibroblast growth factor-23 (FGF23) are associated with mortality. In chronic kidney
disease (CKD), FGF23 levels rise as renal function declines. We analyzed the contribution of laboratory values to the
variance of FGF23 levels in relationship to a curve of expected FGF23 levels for a given GFR.
Methods: Following approval by the research ethics boards, we measured FGF23, CysC eGFR, creatinine, urea,
albumin, calcium, phosphate, vitamin D metabolites, PTH, alkaline phosphatase, CRP, and venous gases in 141
pediatric CKD patients (45, 37, 32, 13 and 14 CKD stages I, II, III, IV, and V, respectively). Data were expressed as
median (25th, 75th percentile).
Results: FGF23 correlated significantly with CysC, CysC eGFR, PTH, 1.25 (OH)2 vitamin D, phosphate, and pH. The
correlation of the latter three remained significant in the multivariate analysis. We calculated a formula for the
expected FGF23 value for a given level of eGFR which reads Y = 1295 * e-0.07247*X + 38.35. Deviation by more
than 20% from the curve also depended on phosphate, 1.25 (OH)2 vitamin D and pH.
Conclusions: Our data emphasize the importance of phosphate and 1.25 (OH)2 vitamin D levels. The impact of
acidosis on FGF23 warrants further studies.
Keywords: Chronic kidney disease, Fibroblast growth factor 23, pH, Cystatin C (CysC), GFR, Parathyroid hormone
(PTH), Vitamin D metabolites
Background
Fibroblast growth factor 23 (FGF23) is a 26 kD phospha-
turic hormone with a mean level of 35 pg/mL (8.8, 120)
in healthy children. [1] It exponentially rises with wors-
ening kidney function and is strongly associated with
cardiovascular morbidity [2–7] and mortality in patients
with chronic kidney disease (CKD). [8, 9] FGF23
strongly correlates with glomerular filtration rate (GFR)
[10, 11] and cystatin C (CysC) in particular. [12] Both
FGF23 and CysC are low molecular weight proteins
(LMWPs) that accumulate with worsening GFR. It is not
yet clear whether higher FGF23 levels occur as a: (i)
compensatory response to decreased renal capacity to
excrete phosphate [13–15]; (ii) result of the use of
calcium-based phosphate binders [16]; (iii) result of de-
creased 1,25 vitamin D3 levels; (iv) result of secondary
hyperparathyroidism [17]; (v) or whether this is related
to the disease process of CKD alone, as LMWP blood
concentrations are greatly influenced by the GFR. [12,
18, 19] Furthermore, nutritional factors and uremic
toxins may also increase FGF23-concentrations. [20, 21]
The objective of the current manuscript was to deter-
mine expected FGF23 levels for given levels of CysC
GFR and to determine which other parameters would be
associated with a deviation in FGF23 concentrations.
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Methods
Study population
We received ethics approval for this cross-sectional
study from the University of Western Ontario
(REB#16962E) and from McMaster University (REB#12–
537). Written informed consent was signed by parents
in every case, and in case of a consenting minor, written
assent was signed. All patients between the ages of 2
and 18 years with CKD stage I-V at the London Health
Sciences Centre, London, Ontario, or McMaster
Children’s Hospital, Hamilton, Ontario, were eligible to
participate. We considered CKD patients, including
those with hyperoxaluria after combined liver-kidney
transplantation, cystinosis, ADPKD (albeit these patients
have recently been shown to have higher FGF23 levels
[22]) or diabetic nephropathy, but excluded those with
Jansen’s Disease and autosomal dominant hypophospha-
temic rickets as these disorders can affect FGF23 levels.
Renal transplant patients were included, but dialysis pa-
tients and patients with x-ray-diagnosed vascular calcifi-
cations were not considered for this study. Nine patients
with tubulopathies and CKD were included even though
they may have had biochemical findings such as phos-
phate and bicarbonate irregularities that could have af-
fected FGF23 levels. This was deemed acceptable as
patients with advanced CKD typically have a degree of
tubular dysfunction. 193 patients were screened; 49 ei-
ther did not consent, did not have sufficient samples
drawn, or were >18 years of age (the study was originally
designed to include young adults up to the age of 40).
We recruited 144 pediatric patients without evidence of
cardiovascular disease at the various stages of CKD: 40%
(I), 21% (II), 21% (III), 10% (IV), and 8% (V). Written
and informed consent were obtained for each patient.
We also assessed whether the patients received an
angiotensin converting enzyme (ACE) inhibitor or an
angiotensin II receptor blocker (ARB), calcium carbon-
ate, an erythropoietin stimulating agent (ESA), or an ac-
tive vitamin D analog. If applicable, a low phosphate diet
was prescribed, but we did not monitor adherence.
Adjustments were not made for the type of metabolic
bone disease, but based on alkaline phosphatase and
parathyroid hormone (PTH), none of the patients had
adynamic bone disease.
Laboratory testing
We collected serum to measure FGF23 and CysC levels
in conjunction with routine blood work regularly ob-
tained when monitoring pediatric CKD patients. Since
CysC concentrations measured before the introduction
of the international reference intervals [23] with the
Dade Behring assay measure lower, we multiplied CysC
measurements by 1.1 in order to ensure that they con-
form with the new international standards [Conversion
factor provided by Dr. Carola Wagner, Siemens Healthcare,
personal communication]. Additional measurements
included phosphate, calcium, ionized calcium, serum albu-
min and total protein, bicarbonate, vitamin D metabolites
(1, 25-dihydroxy- and 25-hydroxyvitamin D), and intact
PTH levels. All were measured using standard laboratory
tests. CysC estimated GFR (eGFR) was calculated using the
Filler-formula. [24] Serum PTH concentrations were
assayed using a solid-phase, two-site chemiluminescent
enzyme-labelled immunometric assay (Immunlite 2000
Intact PTH from Diagnostic Products Corporation, Los
Angeles, CA, USA).
Analytical validation of FGF23 assay
Serum FGF23 levels were measured using a sandwich
enzyme-linked immunosorbent assay (ELISA) system
that incorporates two types of monoclonal antibodies,
requiring the presence of both the N-terminal and C-
terminal portions of FGF23 (Kainos Laboratories, Inc.,
Tokyo, Japan; Millipore, St. Charles, Missouri, USA).
The manufacturers’ instructions were followed and each
antibody-coated well contained 50 μL of serum sample
and 50 μl of assay diluent. Over a span of 2 h the plate
was then incubated at room temperature on a plate
mixer. After 4 washes, the plate was incubated with
FGF23 conjugate, mixing for 1 h at room temperature.
Substrate was then added and allowed to develop for
30 min following another 4 washes. The signal was read
in a microplate reader at 450 nm absorbance within
10mins. [25] Inter-assay and intra-assay coefficients of
variation were 5.0 and 3.0%, respectively. CysC was
measured using the Siemens Healthcare nepholo-
metric assay (PETIA) on a BN-Prospec platform
(Dade-Behring). [24, 26]
Data analysis
Simple descriptive statistics were used whenever
possible. Contiguous data were subject to normality test-
ing using the Shapiro-Wilk normality test. Normally dis-
tributed data was analyzed using parametric methods
(mean, standard deviation, t-test, Pearson correlation,
ANOVA), while the other data were analyzed using non-
parametric methods (median, 25th percentile, 75th per-
centile, Mann Whitney t-test and Spearman rank
correlation). We classified correlations based on the rho
value as follows: strong correlation >0.70, medium cor-
relation 0.30–0.60, mild correlation <0.30. Non-linear
curve fitting (one-phase exponential decay) generated
the function of the non-linear regression model for
FGF23 and eGFR, formulating a line of expected FGF23
concentrations with their corresponding eGFR levels.
We chose one-phase exponential associations because
the small molecular weight of FGF23 should behave
similarly to that of CysC. Contingency tables were
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analyzed using the Chi square test. We then calculated
the percentage above and below the expected concentra-
tion for each FGF23 value, classifying each as within,
below, or above 20% of the expected value. Twenty per-
cent was chosen so to have roughly equal numbers of
measurements within the expected range as well as
above and below the expected range. This analysis was
limited to higher stages of CKD as only negligible
deviation occurred in lower stages of CKD. Finally, we
compared all parameters with regard to these three cat-
egories to identify which laboratory measures explained
a level outside 20% of the expected value using ANOVA.
The last calculations were limited to patients with CKD
stage III-V. No adjustments were made for missing data.
All statistical analyses were performed using the statis-
tical software GraphPad Prism version 5.0 (GraphPad
Inc., San Diego, CA, USA) and IBM SPSS Statistics ver-
sion 21 (IBM Canada Corporation, Markham, ON,
Canada). A p-value of <0.05 was considered statistically
significant.
Results
Patient characteristics are given in Table 1. Forty-one pa-
tients had congenital anomalies of the kidney and urinary
tract (CAKUT), 34 were renal transplant recipients, 28 had
a glomerulopathy or glomerulonephritis (mostly focal and
segmental glomerulosclerosis), 11 had hemolytic uremic
syndrome (HUS), nine patients had a tubulopathy, and 17
had other diagnoses. CKD stage variation was as follows:
CKD stage I (eGFR > 90 mL/min/1.73 m2): 40%; CKD stage
II (eGFR 60–89 mL/min/1.73 m2); 21%, CKD stage III
(eGFR 30–59 mL/min/1.73 m2); 21%, CKD stage IV (eGFR
15–29 mL/min/1.73 m2); 10% and CKD stage V (eGFR
<15 mL/min/1.73 m2): 8%. Three patients with CKD stage
II received bicarbonate. Of the 51 patients with CKD stage
III-V, 23 received ACE or ARB therapy, 16 received calcium
carbonate, 1 received amphojel, 1 received renagel, 24
received bicarbonate, 6 received potassium citrate, 18 re-
ceived ESA, and 19 received vitamin D analogs. Only 5
patients received recombinant human growth hormone.
Since previous studies have shown that CysC moder-
ately correlates with FGF23 concentrations, we calcu-
lated a predicted curve of expected FGF23 levels
(ΔFGF23) for given CysC eGFR values (Fig. 1). We then
performed a correlation analysis of the key laboratory
measures, both for the FGF23 concentrations and the
deviation from the predicted line for a given level of
GFR (Table 2). Phosphate correlated strongly with
FGF23, and PTH correlated moderately and positively
with FGF23. While 1,25(OH)2 vitamin D levels corre-
lated mildly and negatively with FGF23, 25(OH) vitamin
D did not. There was no adjustment for 1,25(OH)2 vita-
min D analogue supplementation. As expected, CysC
eGFR correlated moderately and negatively with FGF23.
We analyzed FGF23 by CKD stage and the deviation
from the expected FGF23 level for a given eGFR using
box-plot graphs (Fig. 2). While FGF23 minimally deviated
from the expected values in CKD stages I and II, CKD
stage V was found to have the largest deviation (Fig. 2).
We then used linear regression analysis (even though
some of the parameters were not normally distributed)
to determine the univariate components of the variance
of FGF23. Phosphate correlated moderately (r2 = 0.441,
p = 0.000), and PTH (r2 = 0.261, p = 0.028) and
1,25(OH)2 Vitamin D (r2 = 0.107, p = 0.000) correlated
weakly with FGF in the univariate linear regressions.
Table 1 Clinical and laboratory parameters of the 144 patients
with CKD stages I-V
Parameter Unit Mean or Median,
as appropriate
STD or IQR,
as appropriate
Age years 12 (6.5, 16.0)
Gender
Height cm 140.7 (116.6, 160.1)
Weight kg 36.6 (20.8, 53.4)
Systolic Blood
pressure
mm Hg 108 13
Diastolic Blood
Pressure
mm Hg 65 11
pH 7.36 0.05
CO2 mmol/L 48 (41, 52)
Bicarbonate mmol/L 26 (23, 28)
Urea mmol/L 7.4 (5.0, 13.4)
Creat umol/L 74 (51, 155)
Ht/Creat Ratio cm * L/umol 2.09 (1.38, 3.3)
CysC mg/L 1.20 (0.88 2.16)
CysC eGFR mL/min/1.73 m2 74 (39, 106)
CysCxPTH mg x pmol/L2 4267 (2687, 6620)
FGF23 pg/mL 50 (37.17, 90.16)
Calcium mmol/L 2.37 (2.27, 2.47)
Phosphate mmol/L 1.31 (1.19, 1.49)
25-OH Vit D nmol/L 64 (49.95, 87.05)
1,25 (OH)2 Vit D pmol/L 76 (50.5, 109.5)
Alk Phos U/L 184 (102.5, 246)
PTH pmol/L 5.9 (3.65, 11.3)
Ionized Ca mmol/L 1.16 (1.1, 1.2)
CRP mg/L 1.05 (0.6, 3.5)
Albumin g/L 43 (39.25, 46)
Total Protein g/L 71 (61, 74)
UCa mmol/L 0.74 (0.46, 1.985)
UCreat mmol/L 5 (2.8, 9.2)
UAlb mg/L 31.9 (7.8, 121.5)
MA/Cr Ratio mg /mmol 8.7 (1.9, 37.3)
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Forty-four percent of overall FGF23 variance may be
explained by phosphate, while 26% of elevated FGF23
may be explained by PTH and 11% by a decrease in
1,25(OH)2 vitamin D levels. Rises in FGF23 were associ-
ated with lower levels of calcium and 1,25(OH)2 vitamin
D levels (r2 = 0.123, p = 0.000; r2 = 0.107, p = 0.000).
Table 3 lists the differences between markers that inter-
act with FGF23 at the different stages of CKD.
To assess the interdependency and collinearity of the
parameters, we then performed a multivariate analysis
using logistic binary regression. Although we wanted to
test all five of the parameters that correlated with FGF23
(phosphate, PTH, 1,25 (OH)2 vitamin D, ionized calcium
and bicarbonate level), the model became unstable if
more than 4 parameters were examined at the same
time. We therefore detailed 5 different combinations
with four variables for each model to assess the impact
of all parameters that correlated with FGF23. We used a
cut-off point of >230 pg/mL for FGF23 in all of the
models. In the first model, the two most important vari-
ables that predicted higher FGF23 levels were CKD stage
and phosphate, even when controlling for 1,25(OH)2
vitamin D levels and PTH. In Model 2, only 1,25(OH)2
vitamin D levels remained significant when controlling
for the covariates. Maintaining a 1,25(OH)2 vitamin D
level > 50 pmol/L was a protective factor for high
FGF23 levels. In Model 3, 1,25(OH)2 vitamin D levels
and phosphate were the only significant parameters after
controlling for the covariates. Maintaining a phosphate
level < 1.60 mmol/L was protective for maintaining an
FGF23 level < 230 pg/mL in 95% of cases. In Model 4,
neither CRP nor bicarbonate level influenced FGF23
after controlling for covariates. Finally, in Model 5, a pH
>7.35 was associated with higher FGF23 levels, even
after controlling for all covariates. The analysis suggests
that correcting renal acidosis over a pH of 7.35 may be
associated with a significant increase in the risk of ele-
vated FGF23 levels.
Finally, we analyzed which parameters accounted for
values within 20% of the expected FGF23 level, or below
and above the 20% band. Only 1,25(OH)2 vitamin D and
phosphate differed between the three groups. Interest-
ingly, overcorrected pH tended to have the worst FGF23
levels. Figure 3 selectively shows C-reactive protein, pH,
1,25(OH)2 vitamin D and phosphate. A lower phosphate
level and a higher 1,25(OH)2 vitamin D level were pro-
tective. Moreover, we tested whether the use of ACE or
ARB, calcium carbonate, ESA, or vitamin D analogs was
associated with higher than expected FGF23 levels.
Whereas more patients with FGF23 levels below or at
the expected range received ACE inhibitors (47.4% ver-
sus 38.5%) and about the same proportion received vita-
min D analogs (31.6% versus 30.8%), this did not reach
statistical significance. In contrast, patients with FGF23
levels below the expected range took about the same
proportion of calcium carbonate (31.6% versus 30.8%),
and less ESA (36.8% versus 44.4%), although this did not
reach statistical significance.
Discussion
Our results confirmed previous findings showing a mod-
erate, non-linear correlation between FGF23 and CysC.
[12] However, using an appropriate multivariate analysis,
Fig. 1 Non-linear regression analysis of FGF23 as a function of Cystatin
C eGFR. Lines representing 20% above and 20% below the expected
concentration are also shown. This curve can be described as Y = Span
* e-K*X + Plateau, where the half-life of the decay is 0.6932/K, Y is the
expected FGF23 concentration, X is the eGFR and the curve begins at
Span + Plateau and ends at Plateau. The values of the curve were:
Span = 1295, K = 0.07247, Plateau = 38.35 and Halflife = 9.565
Table 2 Correlations between parameters that have interaction with FGF23
n = 144 CysC eGFR
[mL/min/1.73 m2]
Phosphate
[mmol/L]
Ionized
Calcium
1,25 (OH)2 Vit D
[pmol/L]
PTH
[pmol/L]
pH Bicarbonate CRP
FGF23 [pg/mL]
(r-rho, p)
−0.548
0.000*
0.667
0.000*
−0.360
0.000*
−0.338
0.000*
0.516
0.000*
0.213
0.029*
0.156
0.071
0.243
0.004*
ΔFGF23 [pg/mL]
(r-rho, p)
0.193
0.021*
0.329
0.000*
−0.144
0.107
−0.043
0.628
0.205
0.018*
0.219
0.026*
0.029
0.743
0.048
0.585
*denotes significant associations (p < 0.05)
FGF23 Fibroblast Growth Factor 23, CysC Cystatin C, Vit Vitamin, PTH Parathyroid Hormone
ΔFGF23 was calculated as measured FGF23 - expected FGF23
As seen in Fig. 1, the expected FGF23 for a given cystatin C concentration can be calculated as Y = 1295 * e-0.07247*X + 38.35, where X is a given cystatin C
concentration and Y is the expected FGF23 concentration
Liu et al. BMC Nephrology  (2017) 18:204 Page 4 of 10
only the effects of phosphate and 1,25(OH)2 vitamin D
levels were statistically significant. The correlation be-
tween FGF23 and CysC is not surprising, given that both
are low molecular weight proteins of similar size that ac-
cumulate in CKD. Using a one-phase exponential decay
model, we calculated expected FGF23 levels for a given
CysC eGFR and analyzed the relationship between the
deviation of the expected value from the measured value
and various clinical laboratory parameters. Only the ef-
fects of 1,25(OH)2 vitamin D and phosphate levels
remained significant. Lower phosphate levels and higher
vitamin D levels were protective, suggesting that normal-
izing both parameters may form the most important
strategy in reducing FGF23 concentrations. Therapy
with ACE or ARBs, calcium carbonate, ESAs and active
vitamin D was not associated with lower or higher
FGF23 levels than expected. Finally, this comprehensive
analysis revealed a novel, previously unreported associ-
ation between pH and FGF23 levels. However, pH in
venous blood is not a robust biomarker and at this point
in time, the impact of the acid-base state on FGF23 re-
quires further study. The data do stress the importance
of serum phosphate and 1,25(OH)2 vitamin D levels for
FGF23 levels, although the optimal target concentrations
remain to be established.
The relationship between FGF23 levels and 1,25(OH)2
vitamin D levels is well described. [27] Experimental
studies demonstrate that direct administration of recom-
binant FGF23 induces a dose-dependent decrease in renal
CYP27B1 mRNA expression, an increase in renal 24-
hydroxylase mRNA expression, and a consequent decrease
in serum 1,25(OH)2 vitamin D concentrations. [28] Phos-
phate is also an independent marker of vascular disease in
CKD [29] and the importance of lowering this marker has
been shown in previous studies. [28] We could not find an
association between ACE inhibition (mostly Ramipril, data
not shown) and FGF23 levels, in contrast to recent findings
in patients with diabetic nephropathy. [30]
The most unexpected finding in our comprehensive
study on biomarker associations with FGF23 concentra-
tions was its association with venous pH. This associ-
ation has not been described in detail and remained
significant even after correcting for all covariates. How-
ever, we must acknowledge that a venous blood gas was
analyzed, which is the weakest means of measuring pH
and is potentially heavily influenced by pre-analytical
error. However, the venous blood gas was determined in
an identical fashion without undue delay during the
transport to the lab. Also, pH affects many systems and
covariables and the changes in pH may only be associ-
ated with FGF-23 increase without inferring causality.
Assuming this association between pH and FGF23 devi-
ation exists, we must interpret this finding: We do know
that pH affects serum calcium concentrations and nor-
mally corrects ionized calcium for a pH of 7.40, so cal-
cium concentrations are higher with a lower pH. It is
understandable that FGF23 would be influenced by pH
due to variability in calcium, which in turn regulates
FGF23 expression in bone. [31] Still, ionized calcium
was no longer significant after controlling for covariates
(Table 4). It is common practice to correct metabolic
acidosis in patients with CKD. [32] Experimental and
clinical studies suggest that correcting acidosis using
alkali therapy attenuates these complications and im-
proves quality of life, although this has not yet been
established. [32] Our results suggest that correcting
metabolic acidosis as well as avoiding a pH of >7.35 in
the venous blood gas analysis may be important in
achieving lower FGF23 concentrations. This recommen-
dation needs to be considered carefully because of the
Fig. 2 This box-and-whisker plot expresses the raises in FGF23 as eGFR
decreases, with a significant p-value (p < 0.0001, ANOVA), as expected.
Data are depicted as median (mid line of the box), 25th (bottom line of
the box), and 75th percentile (top line of the box) and minimum and
maximum (end of the whiskers). ΔFGF23 between the expected and
measured values was not significant, but variability worsened with
worsening CKD stages
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limitations of this study, including the impact of the
concomitant calcium carbonate, bicarbonate, and potas-
sium citrate supplementation. The growth hormone/in-
sulin-like growth factor I axis may also be implicated.
Unfortunately, our numbers were too small to perform a
subgroup analysis.
Major strengths of our study include the sizeable pa-
tient number, the proportion of patients with CKD stage
III or greater, and the robust inclusion of multiple covar-
iates, including CysC, a superior marker of GFR. [33]
Building onto what is known about the relationship
between FGF23 and CysC, this study increases our
knowledge of an area that is woefully understudied. [12,
34, 35] The development of a formula (Y = 1295 * e-
0.07247*X + 38.35, where Y is the FGF23 concentration
in pg/mL and X is the given CysC eGFR level in mL/
min/1.73 m2) to calculate the expected FGF23 concen-
tration for a given level of eGFR is also novel and may
help clinicians better interpret FGF23 levels.
Our study also has several limitations. As this is a
cross-sectional study, associations, even when thor-
oughly checked using binary logistic regressions, do not
denote causality. The role of inflammation could also
not have been studied comprehensively enough because
we did not use a micro-CRP assay and a large number
of CRP values had to be set to the lower detection limit,
which may have obscured a significant association. Some
preliminary data does suggest that FGF23 levels may be
lower with lower levels of micro-CRP. [36] Furthermore,
some conditions that were included such as ADPKD
may be associated with higher FGF23 levels when com-
pared to other causes of CKD. [22] Theoretically FGF23
levels could be higher in patients with cystinosis, but a
PubMed search (search string “Cystinosis AND FGF23”)
revealed no publications. Only one patient of the pa-
tients with tubulopathy had cystinosis with advanced
CKD and the FGF23 concentration was not outside of
the expected range. Klotho was also not measured. pH is
a major outcome variable in our study, but it is only a
venous pH and we had no way to control for the possi-
bility of hyperventilation. Arterial or capillary venous
blood gas studies are not routinely employed in these
patients. A venous blood gas pH of 7.35 likely
corresponds to an arterial blood gas pH of 7.40. pH can
modify calcium levels, but also the sensitivity of the
calcium-receptor and thus PTH metabolism. [37] Al-
though other confounders may be responsible, these
were not elucidated in our univariate analysis. Krieger et
al. recently showed in a neonatal mouse model that
metabolic acidosis induces increased FGF23 in bone.
[38] It should be noted that neonatal kidneys differ
between mice and humans as nephrogenesis only con-
tinues after birth in rodents. Our findings regarding pH
must be confirmed in prospective studies before these
findings are translated into practice. The study was also
underpowered for a multivariate analysis with more than
Fig. 3 pH and phosphate levels of patients with CKD stages 3–5 in relationship to being within 20% or above or below the expected FGF23 concentration
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Table 4 Binary Logistic Regression analysis of five models assessing for collinearity as described in the text
MODEL 1. Condition: FGF23 > 230 pg/mL
In the presence of: Phosphate, 1,25 (OH)2 Vit D, PTH and CKD Stage.
Parameter SE OR (CI 95%) p
Phosphate [mmol/L]
Below 1.60
0.948 0.056
(0.009–0.357)
0.002*
1,25 (OH)2 Vit D [pmol/L]
Over 50
1.033 0.400
(0.053–3.028)
0.375
PTH [pmol/L] 0.016 1.000
(0.969–1.032)
0.968
CKD Stage Cystatin C eGFR [mL/min/1.73 m2] 0.483 2.940
(1.141–7.575)
0.026*
MODEL 2. Condition: FGF23 > 230 pg/mL
In the presence of: Bicarbonate, 1,25 (OH)2 Vit D, PTH and Ionized Calcium.
Parameter SE OR (CI 95%) p
Bicarbonate [mmol/L] 0.107 0.936
(0.760–1.154)
0.536
1,25 (OH)2 Vit D [pmol/L]
Over 50
0.850 0.138
(0.026–0.728)
0.020*
PTH [pmol/L] 0.014 1.026
(0.998–1.053)
0.066
Ionized Calcium
[mmol/L]
4.753 0.002
(0.000–23.520)
0.195
MODEL 3. Condition: FGF23 > 230 pg/mL
In the presence of: 1,25 (OH)2 Vit D, PTH, Ionized Calcium and Phosphate.
Parameter SE OR (CI 95%) p
1,25 (OH)2 Vit D [pmol/L]
Over 50
0.975 0.100
(0.015–0.673)
0.018*
PTH [pmol/L] 0.016 1.014
(0.983–1.047)
0.379
Ionized Calcium
[mmol/L]
4.431 7.980
(0.001–467.56)
0.641
Phosphate [mmol/L]
Below 1.60
0.923 0.045
(0.007–0.277)
0.001*
MODEL 4. Condition: FGF23 > 230 pg/mL
In the presence of: Bicarbonate, CRP, 1,25 (OH)2 Vit D and PTH.
Parameter SE OR (CI 95%) p
Bicarbonate [mmol/L] 0.082 1.021
(0.868–1.200)
0.804
CRP 0.038 0.987
(0.917–1.063)
0.735
1,25 (OH)2 Vit D [pmol/L]
Over 50
0.788 0.110
(0.024–0.517)
0.005*
PTH [pmol/L] 0.014 1.027
(1.000–1.055)
0.053
MODEL 5. Condition: pH > 7.35
In the presence of: FGF23, Ionized Calcium, Bicarbonate and CKD Stage.
Parameter SE OR (CI 95%) p
FGF23 [pg/mL] 0.005 1.009
(1.000–1.019)
0.047*
Ionized Calcium
[mmol/L]
3.325 0.028
(0.000–18.791)
0.281
Bicarbonate [mmol/L] 0.064 0.913
(0.806–1.035)
0.155
CKD Stage Cystatin C eGFR [mL/min/1.73 m2] 0.252 0.588
(0.359–0.964)
0.035*
*denotes significant associations (p < 0.05)
SE Standard error, OR Odds ratio, CI Confident interval. For a significant p value <0.05
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4 covariates. We did, however, solve this problem by
employing multiple models for the binary logistic regres-
sion. The study also lacked the capacity to study the pa-
tients without vitamin D analogue therapy separately.
Conclusions
Nonetheless, the creation of a formula that is able to
provide the expected FGF23 level for a given level of
eGFR is a step towards improving our knowledge and
clinical application of FGF23 in CKD. Our comprehen-
sive analysis confirms the importance of phosphate and
1,25 (OH)2 vitamin D levels in relation to FGF23. The
relationship between FGF23 and pH has not previously
been described and warrants further study. The study
findings must be confirmed in additional prospective
studies such as in the CKiD study.
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